Shares of Neurocrine Biosciences (NASDAQ:NBIX) have received a consensus rating of “Buy” from the fifteen brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $94.00.
Several analysts have commented on the stock. BidaskClub downgraded shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Monday. Oppenheimer reissued a “buy” rating on shares of Neurocrine Biosciences in a research report on Wednesday, March 21st. Piper Jaffray reissued an “overweight” rating and issued a $113.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, March 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $110.00 target price (up from $95.00) on shares of Neurocrine Biosciences in a research report on Thursday, February 22nd.
NBIX traded down $0.06 on Friday, reaching $79.91. 627,968 shares of the company traded hands, compared to its average volume of 891,638. Neurocrine Biosciences has a 52-week low of $39.21 and a 52-week high of $92.98. The company has a market capitalization of $6,894.60, a PE ratio of -49.33 and a beta of 0.29. The company has a debt-to-equity ratio of 0.99, a quick ratio of 10.20 and a current ratio of 10.20.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The company had revenue of $94.52 million for the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. equities analysts forecast that Neurocrine Biosciences will post -0.23 earnings per share for the current fiscal year.
In related news, CEO Kevin Charles Gorman sold 105,983 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $80.25, for a total transaction of $8,505,135.75. Following the completion of the sale, the chief executive officer now directly owns 339,482 shares of the company’s stock, valued at approximately $27,243,430.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dimitri E. Grigoriadis sold 86,368 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $78.32, for a total transaction of $6,764,341.76. Following the sale, the insider now directly owns 154,717 shares of the company’s stock, valued at $12,117,435.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 367,136 shares of company stock valued at $30,001,192. 4.80% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its holdings in shares of Neurocrine Biosciences by 2.6% during the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after buying an additional 140,639 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Neurocrine Biosciences by 3.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 181,751 shares of the company’s stock worth $11,135,000 after buying an additional 5,554 shares during the period. Chicago Equity Partners LLC bought a new stake in shares of Neurocrine Biosciences during the 4th quarter worth $2,759,000. USA Financial Portformulas Corp bought a new stake in shares of Neurocrine Biosciences during the 4th quarter worth $505,000. Finally, Ameriprise Financial Inc. bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth $1,633,000.
TRADEMARK VIOLATION NOTICE: “Analysts Set Neurocrine Biosciences (NBIX) Price Target at $94.00” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/05/analysts-set-neurocrine-biosciences-nbix-price-target-at-94-00.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.